Hoʻonohonoho ʻia ʻo AI-Designed Peptide Synthesis Feasibility i ka Loop Rate

Pane wikiwiki

Why AI-designed peptide synthesis feasibility, modification constraints, orthogonal confirmation and batch comparability set the design-test-learn loop rat

No ke aha i neʻe ai ka Bottleneck mai ke kumu hoʻohālike i ka noho

he papa hema e hōʻike ana i kahi papa inoa o nā kaʻina peptide i hana ʻia ma ka pale a me kahi papa ʻākau e hōʻike ana i nā hue., he hiʻohiʻona chromatogram a me kahi spectru nuipaʻa

ʻO kahi kanaka ʻepekema AI kahi ʻōnaehana multi-agent e hana a hoʻonohonoho i nā kuhiakau noiʻi; ʻO ka ʻaoʻao ʻaoʻao ʻaoʻao nā mea āpau ma waena o kahi moho i koho ʻia a me kahi hue o nā mea kikoʻī. Ua ʻoi aku ka mana o ke kŘkohu ma mua o ia interface, a o ka hakahaka kahi e nalowale ai na loaa.

ʻO nā hōʻoia hōʻike a Google ka mea hōʻike maʻalahi loa. ʻO kāna hui ʻepekema Gemini multi-agent i manaʻo i nā moho e hoʻihoʻi hou i ka maʻi leukemia myeloid i kaohi ʻana i ka hiki ʻana o KG-1 ma nā ʻano koʻikoʻi pili pono., nā pahuhopu epigenetic i hōʻike i ka hana i nā organoids hepatic kanaka (p < 0.01), a me kahi hana cf-PICI/phage-tail no ke kū'ē antimicrobial (ʻImi Google, 2025-02-19). E heluhelu i ka paʻi maikaʻi: ua hoʻopuka ka ʻōnaehana i nā kuhiakau, ʻaʻole mea. Ua lilo kēlā me kēia mau koi i kuleana ma hope o ka hana wet-lab, a i ka manawa i ʻike ʻia ai nā hopena co-scientist mua i nānā ʻia ma Nature, Ua maopopo ka uhi ʻana i ka hōʻoia ʻana o ka lab, ʻaʻole ke kumu hoʻohālike, lawe i ke kaumaha hōʻike (IEEE Spectrum, 2026).

Hoʻonohonoho ʻia ʻo AI-Designed Peptide Synthesis Feasibility i ka Loop Rate

Hoʻopuka hou ke kumu ma ke kahua. Ua ʻike ʻia ka loiloi ʻana o ʻeono mau papa hana ʻike ʻae ʻaʻohe mea i kākoʻo piha i kekahi 15 nā papa hana honua maoli, a me nā hana kikoʻī peptide ʻaʻohe uhi, me nā ʻōnaehana e pili ana i nā hōʻike mole liʻiliʻi (hoʻopaʻa loiloi, 2026-02-13).

ʻAʻole hewa pōʻai ka papa kino. ʻO ka 16-mer like, ʻeono resins, he elima palahalaha i ka maemae ole: hōkū pā[75–90] mai 20% i 52% me ka loaʻa ʻole o kahi hōʻailona solubilizing a 41% i 72% me kahi ArgTag (ʻO ke aʻo ʻana i ka resin SPPS, 2025-11-21). Hoʻohui like ʻia ka pono o kēlā me kēia ʻanuʻu: 99% pau 30 hāʻawi koʻikoʻi nā koena 74% hua nui, 98% hāʻawi e pili ana 55%, a 95% hāʻawi e pili ana 21% (mea wehewehe hana, 2026-07-24). ʻO kēlā pūʻulu hope he kiʻi helu helu, ʻaʻole i ana ʻia ka ʻikepili hoʻolaha, a ʻokoʻa nā kiʻi o kēia ʻano ma ke kumu.

Hoʻonohonoho ʻia ʻo AI-Designed Peptide Synthesis Feasibility i ka Loop Rate

Ki Takeaway: He kumu hoʻohālike e hoʻonoho maikaʻi ana i nā moho e hāʻawi mau i ka waihona i kahi mole nona ka hiki ke hana, ʻAʻole i hoʻoholo ʻia ka hoʻololi ʻana a me ka hōʻoia analytical. ʻO AI-designed peptide synthesis feasibility ka mea i hoʻonohonoho i ka mea hiki ke hoʻopuka maoli.

Hoʻohuihui Peptide ma waena o nā resins synthesis ʻeono me PS-2CTC kumulāʻau pilote, ʻelua moʻo no ka resin (me ka ʻole o ArgTag / me ArgTag). Waiwai me ka ʻole/me: 20/41, meheu/24, 45/72, 52/58, 51/64, 34/64, 27/50. Puna: PMC12645436, 2025.]

ʻO ka Synthesis Feasibility kahi kānana hoʻolālā, ʻAʻole he Post-Hoc Check

he kaulahao peptide hoʻokahi i huki ʻia ma ka ʻaoʻao hema a me ka ʻaoʻao N-terminal a me C-terminal i kaha ʻia, i hōʻike ʻia kahi kiko hydrophobic, he co sterically hindered

Pono ka hiki ʻana o ka peptide synthesis AI-designed e puka i kahi moho ma mua o ke kau ʻana o kekahi i kahi kauoha, ʻaʻole wehewehe i ka hemahema ma hope. E mālama iā ia ma ke ʻano he kānana hoʻolālā: he pale pae kaʻina e holo ana ma ke kumu hoʻohālike, ma ka loop like me ka hana helu.

ʻO ke kaupaku kūpono e hana nui ʻia e nā chemists synthesis he pōkole. Ma luna aʻe 15 nā ʻakika amino, lawe ʻia nā huahana ʻōpala paʻa i ka nui o nā huahana haʻahaʻa haʻahaʻa, a ʻoi aku ka nui o kēlā mau huahana i ka peptide i hoʻopaʻa ʻia i loko o ka pala (ʻO ka loiloi hana SPPS, 2025). Ma luna o 35-40 koena, Hoʻopau ka SPPS i ke ala kūpono a hoʻopaʻa ʻia ka condensation a i ʻole ka ligation kemika maoli (loiloi like, 2025).

Hōʻike ka helu helu i ke kumu. Ma ka 95% i kēlā me kēia ʻanuʻu, hoʻi mai kahi kaulahao 30-koena ma kahi o ka hapalima o ka manaʻo; pau 100 koena, a 1% ʻO ka pau ʻana o kēlā me kēia ʻanuʻu e waiho ma kahi o ka ʻewalu o ka manaʻo (Mea wehewehe peptide synthesis, 2026). ʻO nā kiʻi ʻelua he kiʻi helu helu, ʻaʻole i ana ʻia ka ʻikepili hoʻolaha.

Kōkua nā helu Synthesizability maanei, me na palena. Ua hōʻoia ʻia ka SAscore e kūʻē i nā hoʻoholo chemist ma r² = 0.89 ma na molekala he kanaha, kahi liʻiliʻi (RSC Chemical Science, 2025), a ua hoʻonohonoho ka palapala i nā helu e like me nā mea hoʻolaha mua, ʻaʻole hōʻoia o ka hana ʻana (ʻO ke aʻo ʻana kānana synthesizability, 2026).

Ki Takeaway: E hoʻokaʻawale i nā pilikia hiki ke hoʻokō (aggregation propensity, hydrophobic kikoo, topology multi-disulfide, sterically hindered coupling) mai nā mea pili i ke ala (hoʻolālā pale, koho resin, nā kūlana hoʻomaʻemaʻe a me ka hoʻomaʻemaʻe). ʻO ka mea mua he kaohi hoʻolālā; ʻo ka lua he koho kaʻina.

Loaʻa nā Kaohi Hoʻololi i ka Generation Step

ʻO nā kaohi hoʻololi peptide kahi hoʻokomo manawa-hanau, ʻaʻole he hoʻomaʻemaʻe manawa. Pono e nānā ʻia ka kemika i manaʻo ʻia a me ke ala synthesis maoli ma mua o ka hana ʻana o kahi kumu hoʻohālike i kahi moho., no ka mea, ʻaʻole hiki ke ʻike ʻia ke ala i kahi helu kūkulu wale nō. ʻO nā hiʻohiʻona he mau hiʻohiʻona kūpono, ʻaʻole physics: hōʻike ʻia nā loiloi loiloi ʻana o ka multi-agent peptide-design frameworks e kaupalena ʻia kēia mau ʻōnaehana e ka ʻikepili hoʻokolohua kiʻekiʻe., Nawaliwali ka lawelawe ʻana i nā peptides maʻalahi, a me ka hilinaʻi ʻana i nā ʻano helu helu ma mua o ke kemika kino (Nā ʻōlelo pōkole ma Bioinformatics, 2024; Nā Kūkākūkā Kimia, 2026).

ʻO kēlā āpau kahi e loaʻa ai kahi hōʻike kūpono. He moho e lawe ana i ka lipidation, cyclization a i ʻole kahi hōʻailona fluorescent pono e hoʻokō i kahi papa kuhikuhi hoʻololi e uhi ana i ka kemika i manaʻo ʻia ma mua o ke kau ʻana i kahi kauoha., ʻaʻole ma hope o ka hāʻule ʻana ʻO nā Peptides Synthetic hailona. Ma ka hoʻomaʻamaʻa ʻana he hoʻololi pōkole kēia: kaʻina i loko, hoʻololi i manaʻo ʻia, ala a me ka hiki ke heluhelu hope. Kahi e kū ai ka papa kuhikuhi, ʻO ka CDMO kūpono a i ʻole ka mea hoʻolako loea ka pane pololei, a ʻo ka mea hoʻoponopono ka hoʻokolohua.

Hoʻokahi Heluhelu ʻAʻole ia he hōʻoia

ʻO ka hōʻoia ʻana o Orthogonal analytical o nā peptides ke ʻano o ka hoʻohana ʻana i nā ʻano kumu kino no ka hoʻokaʻawale a ʻike ʻana i kahi mole he kūʻokoʻa maoli., ʻaʻole ʻelua holo o ka loina like. Hōʻike ʻia kahi ʻāpana HPLC hoʻokahi hulina i ka hailona elutes e like me ka piko hoʻokahi; ʻAʻole ia e haʻi iā ʻoe he aha kēlā piko. Manaʻo ka papa inoa ponoʻī o ka FDA o nā hemahema i nā faila peptide hoʻohālikelike i nā ʻano chromatographic orthogonal me nā kumu hoʻokaʻawale like ʻole me ka UHPLC-HRMS/MS e hōʻoia i ka ʻike kiʻekiʻe. (FDA comparative-peptide-analysis alakaʻi, 2022-09-20). I Q2(R2) hoʻonohonoho i nā hiʻohiʻona hōʻoia no kēlā me kēia ʻano kaʻina hana a hiki ke hōʻike ʻia ka kikoʻī i ke kekona, kaʻina hana maikaʻi, me kahi orthogonal (I Q2(R2), 2023-11-30). Hoʻonohonoho ʻo Q6B i nā kikoʻī mai nā ʻāpana hana-kūlike, ʻo ia ke kumu no ka ʻae ʻana i ka hailona, aole i ka hoao ana (I Q6B).

pae haumia

Nā lawelawe Pono ka hana

≥0.10%

Hōʻike

≥0.5%

E hoomaopopo

≥1.0%

Kupono

>0.5% haumia hou vs. huahana kuhikuhi

ʻAʻole acc hale kūʻai eptable

Nā paepae ma ke alakaʻi FDA (2022-09-20) a me ka EMA synthetic-peptide alakaʻi (2025-12-04).

ʻO ke ʻano papa hoʻi: kūlana maikaʻi ka moho ma ka silico, synthesizes e like me ka haʻahaʻa-hoʻihoʻi crude, hoʻomaʻemaʻe maikaʻi ʻole, a hāʻawi mai i ka nui nona ka heluhelu ʻana i ke ala hoʻokahi e ʻae ʻia ʻoiai ʻaʻole ʻae ke ʻano o ka orthogonal.

Pono e ʻike ʻia ka palapala ʻike a me ka maʻemaʻe i nā faila ʻikepili maka no kēlā me kēia lot, a ʻaʻole hiki ke hōʻoia ʻia kahi CoA me ka ʻole o ka chromatogram a me ka spectrum nuipaʻa. Hana ʻia ʻo Peptide

ʻO ka hoʻohālikelike ʻana ʻo Batch kahi hoʻokomo hoʻolālā

hoʻokahi ʻaoʻao CoA i waiho ʻia me kāna mau kahua i kapa ʻia - helu helu, helehelena, maʻemaʻe e HPLC me ka hoʻokomo chromatogram, ʻike ʻia e MS me ka spec

ʻO ka hoʻohālikelike ʻana o ka peptide batch-to-batch ka hiki ke hōʻike i ʻelua mau ʻāpana like o ke kaʻina like me ka kikoʻī like., a ua hoʻoholo lōʻihi ma mua o ka wehe ʻana o QC i kahi hue. ʻAʻole kahi kikoʻī he helu maʻemaʻe; he hoao ana, nā kaʻina hana a me nā pae hoʻohālike, a pili like na paepae i ka hailona (ʻO ke alakaʻi FDA ma nā palena endotoxin). ʻO ke ala a me nā koho resin he mau mea hoʻohālikelike like: ma kahi 2025 Haʻawina SPPS, hoʻokahi kaʻina i hāʻawi 27% maʻemaʻe maʻemaʻe ma luna o ka resin PS-2CTC kiʻekiʻe ma 0.75 mmol/g, e ala ana i 50% ma 0.69 mmol/g me ka hōʻailona, ʻoiai ʻo apolar PSAM-RAM i hāʻawi ʻokoʻa 20% a ʻo MBHA-RAM wale nō ka huahana trace (ʻO ka haʻawina resin SPPS like). Hāʻule nā ​​huahana i ka holoi ʻana, hoʻopau a me nā hoʻololi kemika, a hoʻololi ko lākou ʻaoʻao me ke ala.

ʻAʻohe mea i paʻi ʻia ʻo 2025–2026 ka hāʻawi ʻana i ka puʻupuʻu maʻemaʻe nui-a-lot no nā peptides paʻakikī i hoʻololi ʻia me nā peptides laina maʻalahi.. ʻO ka mea e hoʻoponopono ai ka moʻolelo ʻo ia ka papa hoʻokuʻu: lawe ka sterility 14 mau lā i loko o ʻelua pāpaho i ʻelua mahana ma mua o ka loaʻa ʻana o kahi hopena sterility, me ka ulu ʻole o kēlā me kēia mea e pono ai (ʻO FDA Pharmaceutical Microbiology Manual), a hoʻokolokolo ʻia ka endotoxin e kūʻē i ka 5 EU/kg ka palena makua, helu ʻia ʻo K/M (ʻO ke alakaʻi FDA ma nā palena endotoxin). Hoʻopaʻa ʻia kahi palapala hoʻopaʻa palapala pākahi i ka helu ʻāpana, helehelena, ka maemae e ka HPLC me ka chromatogram, ʻike e MS me ka spectrum, a me nā hopena endotoxin a me ka sterility, hiki ke ʻimi ʻia kēlā me kēia i kāna faila ʻikepili maka.

Hoʻonohonoho ʻia ka Loop Rate e ka Analytical Turnaround, ʻAʻole ʻo Inference Speed

ʻO ka pōʻai hoʻolālā-hoʻāʻo-aʻo no ka ʻike ʻana i ka peptide, ka loop kahi i hoʻolālā ʻia ai kahi moho, synthesized, hoʻāʻo ʻia a hānai hou ʻia i ka puni aʻe, ua pani ʻia e ka manawa alemanaka ma ka noho, ʻaʻole ma ka wikiwiki hoʻohālikelike. I ka loaʻa ʻana o nā moleke liʻiliʻi i alakaʻi ʻia e AI, holo maʻamau ka hoʻolālā-make-test-analyse 4 i 8 pule pule, ʻoiai ʻo nā huaʻōlelo lawelawe peptide e kau i ka synthesis maʻamau ma 1 i 3 mau pule a hoʻololi a lōʻihi paha nā peptides ma 2 i 6 pule pule, me ka huli ho'ā'o mua o 3 i 5 lā, 5 nā lā me ADME, a malalo 10 nā lā me in vivo PK (ʻAhahui BioIndustry, kiʻi ʻia 2026-09-12). ʻO ia nā ʻōlelo kūʻai aku a me ka pae lawelawe, ʻaʻole kahi pae hoʻomalu. AstraZeneca's under-5-day design-to-test-data target and sub-2-hour prototype cycle e hōʻike ana i ke ʻano o ka loop loop i ka wā i hoʻolālā ʻia ai nā ʻanuʻu wai-lab no ka wikiwiki. (IRBM, kiʻi ʻia 2026-09-11).

ʻO ka manawa alemanaka e hoʻopau maoli ai kahi noi synthesis i ke ʻano like: peptides maʻamau o 2 i 30 nā amino acids ma luna 80% hiki mai ka maemae 10 i 15 nā lā ʻoihana, kauoha i loko 5 i 7 lā, a paʻakikī a hoʻonui paha i nā kaʻina hoʻololi i 3 i 4 pule pule. ʻO ka hoʻopōkole ʻana i ka loop, ʻo ia hoʻi ke kūʻai hou ʻana i kēlā mau pule, ʻaʻole e kahi i nā milliseconds mai kahi holo hoʻohālike.

Akā, e hoʻolālā nā kumu hoʻohālike a puni ke kemika - ʻaʻole lākou i hala?

hapa, a he mea nui ka ʻae. He hana maʻamau nā kānana synthesizability papa SAscore, a ʻo ka puke moʻolelo 2025–2026 e mālama i nā helu hiki ke loaʻa ma ke ʻano he mea pono e hoʻolaha mua.. Akā ʻo ka palapala like ʻole i maopopo he mau proxies lākou, ʻaʻole hōʻoia o ka hana ʻana, me ka hoʻokolohua kino i koe i ka arbiter. ʻOi aku ka lahilahi o ka proxy ma mua o kona kaulana: Ua hōʻoia ʻia ka SAscore ma nā molekala he kanahā, a he hoʻolālā wale nō ma mua o ke ala ala. Ma ka ʻaoʻao hoʻohālike, ʻO kahi loiloi o nā papa hana ʻeono i loaʻa i ka uhi ʻana o ka peptide-task ma waena o ʻeono frameworks, me ke kuʻi ʻana i nā hōʻike mole liʻiliʻi, a ʻo ka helu ʻana i lalo he mau hiʻohiʻona kūpono, ʻaʻole physics. Hoʻonui nā kānana maikaʻi i ka helu pā. ʻAʻole lākou e wehe i ka hiki, hoʻololi hoʻololi, hōʻoia orthogonal a me ka hoʻohālikelike ʻana e like me nā hoʻokomo hoʻolālā.

Nā ʻanuʻu aʻe: E mālama i ka Interface e like me ka Papa Hoʻolālā

AI-designed peptide synthesis feasibility, hoʻololi hoʻololi, ʻO ka hōʻoia orthogonal a me ka hoʻohālikelike pūʻulu he mau mea hoʻolālā, ʻaʻole nā ​​​​hōʻoia i lalo, a ua hoʻonohonoho ʻia ka helu loop e ka huli analytical ma mua o ka wikiwiki inference. He pōkole ke kaʻina hoʻomaka. E pale i nā moho e kū'ē i nā lula kūpono kūpono ma mua o kou kauoha ʻana i kekahi mea. E nānā i ka hoʻololi i manaʻo ʻia e pili ana i ke ala e holo maoli ai. Koi i ka hōʻoia orthogonal me kēlā me kēia lot raw-data traceability. E wehewehe i nā pae hoʻohālikelike i loko o ke kauoha ponoʻī, ʻaʻole ma ka leka uila ma hope o ka hiki ʻana o ka hailona mua.

ʻO MOL Changes kahi peptide kūikawā R&ʻO ka hui D e hoʻohui ana i ka kemika organik a me ka biology, hāʻawi i ka synthesis maʻamau mai ka hoʻolālā ʻana i ka hana nui, me ka hana ma ka Papa 100 nā lumi hoʻomaʻemaʻe ultra-sterile a me QC e MS, HPLC, AAA, endotoxin, kūʻē, ka hoʻololi ʻana a me ka ʻike UV. Loaʻa i ka MOL Changes kahi hoihoi pāʻoihana i nā kūlana maikaʻi peptide. ʻAʻole ʻo ka hoʻopiʻi ʻana i ke ʻano o ka pae hoʻomohala, a ʻo ka hoʻoholo ʻana a i ʻole ka hoʻoholo dosing pili i nā ʻoihana kūpono.

E hoʻouna i kahi kaʻina no kahi heluhelu kūpono. Loaʻa iā ʻoe kahi loiloi ala a me kahi manawa kūpono ma mua o kou hoʻokō ʻana i kahi kauoha, ʻo ia ke ala haʻahaʻa loa e ʻike ai inā hiki i kahi moho ke noho i loko o kahi hue. E pili ana

Nīnau pinepine

Mai hoʻoponopono i nā kānana synthesizability i kēia?

hapa, a ʻo ia ka pane pololei. ʻO nā kānana he mau proxies pono, aole palapala. Ua hōʻike ʻia kahi hoʻonohonoho hōʻoia 40-molele e ʻokoʻa pinepine ka synthesizability a me nā hopena pae i hiki i kahi kānana ke koho i nā moho akā ʻaʻole hiki ke hoʻomaʻemaʻe i kekahi.. E mālama i ka helu hala ma ke ʻano he ʻae e hoʻāʻo, ʻaʻole loa e like me ka hōʻike ʻana o ka mole.

Ua paʻa mua kā mākou papahana i nā moho i hiki ʻole ke kūpono. I kēia manawa he aha?

E hoʻonohonoho hou i ke ala ma mua o kou hoʻolālā hou ʻana i ka mole. ʻO ka hōʻiliʻili ʻana o nā huahana i lilo i mea koʻikoʻi ma luna 15 koena, a ke hoʻololi nei ke ala ma luna 35 i 40 koena, kahi e hoʻomaka ai e uku ka convergent ligation. Nui nā ʻano "infeasible" i hiki ke hiki i kahi hoʻolālā hui ʻokoʻa.

ʻAʻole e ʻoi aku ka maikaʻi o nā kumu hoʻohālike a hoʻolālā a puni kemika?

Ke hoʻomaikaʻi nei ka hiki; ʻaʻole ka uhi. ʻEono mau papa hana loiloi nui i loaʻa ka uhi ʻole peptide, no laila ʻaʻole i loiloi ʻia nā frameworks ma nā peptides. Kōkua nā kumu hoʻohālike maikaʻi, akā, pili kino ka hoʻololi ʻana i ka peptide, ʻaʻole ʻike, a ʻaʻohe pae hoʻohālikelike e ana iā lākou i kēia manawa.

He mea nui ka hoʻohālikelike pūʻulu ma ka pālākiō noiʻi, a i ʻole ma ka hana ʻana?

He mea nui i ka wā e hānai ai i ʻelua hailona hoʻokahi hoʻokolohua. ʻO ka hoʻohālikelike he nīnau kikoʻī: wehewehe i nā paepae haumia a me nā ʻano analytical e ana iā lākou ma mua o ka hoʻohālikelike ʻana i nā hopena ma nā hailona, ʻaʻole ma hope o ka hoʻopiʻi ʻana ʻaʻole ʻae.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana